Following a two-year stint as chief strategy officer for Biogen, Adam Koppel took a new job last June helming Bain Capital’s investments in biotech and life sciences. And now he’s gathering the cash for a new fund.
Koppel’s listed in the Form D filed with the SEC for Bain Capital Life Sciences today, where he’s taken the role of managing director. And while it doesn’t list an amount, Bain has a long history of making a splash in whatever field it’s working in, with more than $75 billion in managed capital.
The move was a return to the private equity group, where Koppel had worked in healthcare for 11 years before joining George Scangos’ team at Biogen. And he’ll be working with Jeffrey Schwartz, a Boston-based managing director at Bain.
Koppel didn’t respond immediately to a message from Endpoints News.
He must know the Cambridge/Boston hub intimately by this stage. The Harvard grad got his PhD in neuroscience at the University of Pennsylvania, with an MBA from Wharton.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription